Clinical Trial Detail

NCT ID NCT03268954
Title Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Azacitidine + MLN4924

Azacitidine

Age Groups: adult senior

No variant requirements are available.